We are proud to share that Gedeon Richter has acquired Celmatix Therapeutics’ women’s health discovery portfolio, including our programs spanning infertility, endometriosis, and ovarian aging. The portfolio includes a first-in-class oral FSH receptor agonist, a novel JNK inhibitor for endometriosis, and early-stage AMH-targeting antibodies designed to expand control over ovarian folliculogenesis.
Gedeon Richter today announces the acquisition of the women’s health discovery portfolio of Celmatix Inc., (“Celmatix”) a US-based pioneering women's health biotech company dedicated to translating advances in female biology into novel therapeutics.
The assets acquired from Celmatix include a first-in-class oral Follicle-Stimulating Hormone (FSH) receptor agonist with the potential to transform fertility care by enabling more patient-friendly ovarian stimulation. The portfolio also features a novel Jun N-terminal kinase (JNK) inhibitor, which represents a potential non-hormonal immunotherapy approach for endometriosis aimed at addressing both pain and inflammation. In addition, the acquisition comprises early-stage therapeutic antibodies targeting anti-Müllerian hormone (AMH), including both agonists and antagonists, with the potential to provide unprecedented control over ovarian folliculogenesis.
Celmatix Therapeutics has announced its latest drug program, a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The therapeutic drug candidate, developed using the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine (BCM), aims to address a critical unmet need in first-line treatments for a range of women’s health indications, starting with endometriosis and potentially extending to Polycystic Ovary Syndrome (PCOS) and ovarian aging.
Celmatix Inc. has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health, to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. Celmatix will receive $3.5 million in funding over two years through the Sprint for Women’s Health spark track for early-stage research efforts.
Celmatix Inc. has announced the nomination of a lead compound in its oral Follicle Stimulating Hormone receptor (FSHR) agonist drug development program. This represents a major milestone, with the potential to transform fertility treatments for both men and women. The announcement coincides with the annual meeting of the American Society for Reproductive Medicine (ASRM), currently underway in Denver, Colorado.
